PDE5A and pulmonary arterial hypertension: Phosphodiesterase 5 (PDE5) inhibitors approved to treat PAH are sildenafil, tadalafil and vardenafil [7], whose mechanism involves increasing the bioavailability of cyclic guanosine monophosphate (cGMP) by inhibiting its degradation [8].